Table 3. RFS stratified step-wise multivariate Cox model with TLE3 median cut-point.
| Visual IHC factor | Hazard ratio | 95% CI | P-valuea |
|---|---|---|---|
| Treatment (Trt) EC/T vs CEF | 0.72 | 0.39–1.31 | 0.278 |
| TLE3+ vs TLE3− | 0.76 | 0.44–1.31 | 0.320 |
| Endocrine therapy | 0.18 | 0.08–0.40 | <0.0001 |
| Anti-HER2 therapy | 3.64 | 1.83–7.26 | 0.0002 |
| Interaction of TLE3 andTrt | 1.02 | 0.47–2.24 | 0.957 |
| Interaction of endocrine therapy and Trt | 1.82 | 0.81–4.10 | 0.147 |
| Interaction of anti-HER2 therapy and Trt | 0.58 | 0.15–2.07 | 0.400 |
|
Ariol Image analysis | |||
|
Factor | |||
| Trt EC/T vs CEF | 0.75 | 0.42–1.34 | 0.330 |
| TLE3+ vs TLE3− | 0.77 | 0.46–1.28 | 0.308 |
| Endocrine therapy | 0.23 | 0.11–0.50 | 0.0002 |
| Anti-HER2 therapy | 3.30 | 1.71–6.38 | 0.0004 |
| Interaction of TLE3 and Trt | 1.10 | 0.52–2.31 | 0.809 |
| Interaction of endocrine therapy and Trt | 1.41 | 0.66–3.02 | 0.379 |
| Interaction of anti-HER2 therapy and Trt | 0.57 | 0.17–1.99 | 0.380 |
Abbreviations: 95% CI=95% confidence interval; IHC=immunohistochemistry; RFS= relapse-free survival; Trt=Treatment; Visual IHC=TLE3 staining assessed visually. Ariol image analysis=TLE3 staining assessed using automated image analysis.
a
P-value is based on Wald statistic.